The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 24, 2024
Filed:
Jan. 11, 2021
Applicant:
Fate Therapeutics, Inc., San Diego, CA (US);
Inventors:
Bahram Valamehr, San Diego, CA (US);
Ryan Bjordahl, San Diego, CA (US);
Jode Goodridge, San Diego, CA (US);
Tom Tong Lee, San Diego, CA (US);
Assignee:
Fate Therapeutics, Inc., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/074 (2010.01); A61K 35/545 (2015.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 5/0789 (2010.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61K 35/545 (2013.01); A61K 39/4613 (2023.05); A61K 39/4631 (2023.05); A61K 39/464426 (2023.05); C07K 14/70535 (2013.01); C07K 16/2896 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 5/0647 (2013.01); C12N 5/0696 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A61K 2239/26 (2023.05); C12N 2310/20 (2017.05); C12N 2506/45 (2013.01); C12N 2800/80 (2013.01);
Abstract
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.